[Skip to Content]
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
May 2012

Chemoprevention for Keratinocytic (Pre)cancersBalancing the Risks and Benefits

Arch Dermatol. 2012;148(5):638-640. doi:10.1001/archdermatol.2011.2273

Commentary on: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trialElmets CA, Viner JL, Pentland AP, et al J Natl Cancer Inst. 2010;102(24):1835-1844

Question: Can celecoxib reduce the incidence of actinic keratoses (AKs) and keratinocytic cancers?

Design: Randomized, double-blind, placebo-controlled phase 2-3 clinical trial.

Setting: Eight centers in the United States participated and included 240 patients from January 2001 to November 2006, when the Food and Drug Administration requested termination of this trial after the worldwide withdrawal of rofecoxib.

First Page Preview View Large
First page PDF preview
First page PDF preview